MX2023010825A - Metodos para tratar el cancer con anticuerpos anti-ilt3. - Google Patents

Metodos para tratar el cancer con anticuerpos anti-ilt3.

Info

Publication number
MX2023010825A
MX2023010825A MX2023010825A MX2023010825A MX2023010825A MX 2023010825 A MX2023010825 A MX 2023010825A MX 2023010825 A MX2023010825 A MX 2023010825A MX 2023010825 A MX2023010825 A MX 2023010825A MX 2023010825 A MX2023010825 A MX 2023010825A
Authority
MX
Mexico
Prior art keywords
antigen binding
metastatic
methods
treating cancer
ilt3
Prior art date
Application number
MX2023010825A
Other languages
English (en)
Inventor
Andrey Loboda
Michael Nebozhyn
Philip E Brandish
- HOOVER Jie ZHANG
Mei Chen
Cai Wu
Daping Zhang
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2023010825A publication Critical patent/MX2023010825A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta divulgación se refiere a métodos para tratar tumores sólidos en un paciente identificado por tener cáncer de mama triple negativo metastásico, glioblastoma, adenocarcinoma ductal pancreático metastásico, sarcoma de tejido blando metastásico o carcinoma de pulmón no microcítico no escamoso metastásico, que comprende administrar una proteína de unión a antígeno anti-ILT3, o fragmento de unión a antígeno, y una proteína de unión a antígeno anti-PD1, o fragmento de unión a antígeno, al paciente cada tres semanas (Q3W).
MX2023010825A 2021-03-19 2022-03-17 Metodos para tratar el cancer con anticuerpos anti-ilt3. MX2023010825A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163163779P 2021-03-19 2021-03-19
PCT/US2022/020714 WO2022197900A1 (en) 2021-03-19 2022-03-17 Methods for treating cancer with anti-ilt3 antibodies

Publications (1)

Publication Number Publication Date
MX2023010825A true MX2023010825A (es) 2023-12-08

Family

ID=83320983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010825A MX2023010825A (es) 2021-03-19 2022-03-17 Metodos para tratar el cancer con anticuerpos anti-ilt3.

Country Status (9)

Country Link
EP (1) EP4308243A1 (es)
JP (1) JP2024511977A (es)
KR (1) KR20230158057A (es)
CN (1) CN117412771A (es)
AU (1) AU2022239502A1 (es)
BR (1) BR112023018921A2 (es)
CA (1) CA3212604A1 (es)
MX (1) MX2023010825A (es)
WO (1) WO2022197900A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005128A (es) * 2017-11-17 2020-07-27 Merck Sharp & Dohme Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117205312A (zh) * 2017-01-20 2023-12-12 埃克塞里艾克西斯公司 治疗癌症的卡博替尼与阿特珠单抗组合
MX2020005128A (es) * 2017-11-17 2020-07-27 Merck Sharp & Dohme Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos.
US20220177534A1 (en) * 2018-05-10 2022-06-09 The Regents Of The University Of California Ccl21 and checkpoint inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
BR112023018921A2 (pt) 2023-12-05
AU2022239502A9 (en) 2024-02-22
KR20230158057A (ko) 2023-11-17
CN117412771A (zh) 2024-01-16
WO2022197900A1 (en) 2022-09-22
AU2022239502A1 (en) 2023-10-05
JP2024511977A (ja) 2024-03-18
CA3212604A1 (en) 2022-09-22
EP4308243A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
BR112019010356A2 (pt) molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo
MY202279A (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX344355B (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
MX2011010469A (es) Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
MXPA03001634A (es) Polipeptido tumoral cripto.
MX2010003766A (es) Composicion para el tratamiento de cancer pulmonar, en particular canceres pulmonares no microciticos (cpnm).
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
TW201129380A (en) Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
EA200970607A1 (ru) Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
MX2023010825A (es) Metodos para tratar el cancer con anticuerpos anti-ilt3.
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
EP1968981A4 (en) METHOD FOR TREATING TUMORS WITH AZAXANTHONES
CY1108194T1 (el) Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων
MX2019009121A (es) Antcuerpos anti-kaag1 o fragmento de union al antigeno del mismo para el tratamiento de cancer de mama triple negativo.
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.
DE60038624D1 (de) Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
IL218442A0 (en) Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma
WO2023034336A3 (en) Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility
MX2022016232A (es) Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).
GB9906380D0 (en) Monoclonal antibodies specific for cypibi
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
EP1668120A4 (en) METHOD OF DETECTING CANCER CELLS AND MONITORING ANTICANCER THERAPY